ArticleClinical and experimental hepatology2025
Pemafibrate as a therapeutic option for metabolic dysfunction-associated steatotic liver disease resistant to dietary intervention.
Hideyuki Tamai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.